Search results: (10000)
News Population Pharmacokinetic Model in Patients with von Willebrand Disease
Dutch authors presented a potential population pharmacokinetic model describing levels of von Willebrand factor and coagulation factor VIII during and after surgical procedures in patients with von Willebrand disease.
News Prevention of Skeletal Events in the Therapy of Patients with Advanced Prostate Cancer
Prostate cancer most commonly forms metastases in the bones. In patients with this advanced disease, skeletal events occur, negatively affecting their quality of life. Zoledronic acid and denosumab are used to prevent their occurrence, and their results in this indication were evaluated and compared in the cited study below.
News Two Current Perspectives on the Importance of (Par)enteral Nutrition in Cancer Patients
Adequate (par)enteral nutrition is crucial for cancer patients in terms of prognosis and quality of life. The following recent studies examined parenteral nutrition as an alternative to ileostomy in patients with colorectal anastomosis and muscle mass loss in patients with metastatic cancer.
News Are SGLT2 Inhibitors Only Suitable for the Treatment of Diabetes?
SGLT2 inhibitors, or gliflozins, are effective antidiabetic drugs that have shown nephroprotective and cardioprotective effects in diabetics, repeatedly demonstrated in clinical trials. At the European Cardiology Congress in September 2019 in Paris, results were presented from the DAPA-HF study, where dapagliflozin became the first SGLT2 inhibitor to show benefits in patients with heart failure with reduced ejection fraction of the left ventricle, regardless of whether they had type 2 diabetes or not. The study thus offered a completely new perspective on the treatment of heart failure.
News How trends in sports evolve among hemophiliacs and to what extent they are limited by their disease
Historically, physical activity was generally not recommended for hemophiliacs; however, with evolving treatment options and prophylaxis as the gold standard of care for these patients, sports have become part of their lives in recent years. The Netherlands, traditionally supportive of sports, including for patients with chronic illnesses, presented the results of a survey on hemophilia and sports in a poster presentation at the 13th annual EAHAD congress in The Hague this February.
News Does the Risk of Recurrence of Differentiated Thyroid Carcinoma Differ by Gender?
Differentiated thyroid carcinomas (DTC) are typically diagnosed at more advanced stages in men than in women, and mortality from this disease is higher among men than women. However, it was not entirely clear whether the risk of DTC recurrence is influenced by the patient's gender independently of the disease stage at the time of diagnosis. The aim of the Canadian authors' study was to assess whether male gender is an independent risk factor for DTC recurrence.
News ERS 2022: What Insights Do Studies Focused on COPD Biomarkers Bring?
In this year's scientific program of the international congress of the European Respiratory Society (ERS 2022), there was also a lot of talk about the investigation of biomarkers of chronic obstructive pulmonary disease (COPD) and its acute exacerbations (COPD AE). This topic was also well-represented in the e-poster presentations section. From that section, we select 3 studies whose conclusions are summarized below.
News Does Emicizumab Change Routine Clinical Practice?
With the increasing number of patients with hemophilia A being treated with emicizumab, the question arises whether its use in any way changes established clinical practice. A team of American authors sought answers based on a survey conducted among the treating physicians of these patients. The findings were presented at the 13th Annual EAHAD Congress, which took place at the beginning of February in The Hague, Netherlands.
News IEC 2023: Key Challenges for Epilepsy Patients Include Status Epilepticus and Anxiety Management
Why is anxiety a significant issue for epilepsy patients? What do current insights say about the connection between epilepsy and anxiety? Can artificial intelligence be used to predict status epilepticus (SE)? And what is known about the development of late epilepsy following new SE? These and other topics were discussed in September 2023 in Dublin during the 35th International Epilepsy Congress (IEC 2023).
News Does the emergence of resistance to cetuximab mean ineffectiveness of all anti-EGFR antibodies?
Colorectal cancer (CRC) cells respond to targeted therapy in different ways. Besides the desired outcome of cell death, CRC cells can adapt and survive through changes in their genome. It is important to recognize that the developed resistance to targeted therapy may, but does not necessarily, apply uniformly across a class of drugs or a single mechanism of action.
News Clinical Profile and Outcomes of Patients with Cardiac Amyloidosis – Spanish Experience from Real Practice
Cardiac amyloidosis is caused by the deposition of amyloid fibrils in the myocardium and is among the diseases with significant diagnostic delay. Physicians from the University Hospital in Madrid shared their experiences with the diagnosis and treatment of these patients over the last decade in the cited work below.
News Prokinetics in the Treatment of Diabetic Gastroparesis
One of the common complications of diabetes mellitus is a motility disorder of the gastrointestinal tract, which can affect any part of the digestive tube, and therefore has various forms. Among these therapeutically challenging conditions is diabetic gastroparesis, which involves impaired stomach emptying.
News Can the use of sartans reduce mortality and severity of COVID-19 in hypertensives?
Existing scientific and clinical evidence suggests the involvement of the renin-angiotensin-aldosterone system (RAAS) in the pathophysiology of COVID-19. Some of the initial experimental therapy proposals included various interventions in the RAAS.
News Nonacog Beta Pegol (N9-GP) in Bleeding Prophylaxis in Patients with Hemophilia B – Real World Data
The goal of hemophilia B treatment is currently the prevention of bleeding by administering a coagulation factor IX concentrate. The study presented below brings recent real-world data on treatment outcomes when switching to the latest preparation, nonacog beta pegol (N9-GP).
News HVD 2023: Cervical Cancer May Be the First Eliminated Malignancy. What Paths Will Lead to This Goal in the Czech Republic?
Cervical cancer is the 3rd most common cancer among women aged 15–44. Annually, it is diagnosed in 750–800 women in our country, and every 29 hours, one woman dies from it in the Czech Republic. However, it could become the first oncological disease that can be eliminated. How to achieve this was discussed by the chairman of the Czech Vaccinological Society ČLS JEP and Dean of the Faculty of Military Medicine at the University of Defense in Hradec Králové, Prof. MUDr. Roman Chlíbek, Ph.D., at a symposium supported by MSD during the October XVIII. Hradec Vaccinology Days (HVD).
News The World of Viruses is Constantly Evolving and Bringing Us New Surprises
The last decade has been marked by the emergence of new, as well as re-emerging human pathogens responsible for various infectious diseases. Viruses, especially those of zoonotic origin that originate in the wild, are demanding significant attention—and rightly so. This group of viruses currently accounts for 70% of infectious diseases in the human population, with many using animal organisms as vectors (e.g., ticks, mosquitoes) to transport and infect the human body. Human-vector interactions are becoming increasingly common, particularly due to ongoing urbanization, encroachment into previously uninhabited areas, population migration, increasing travel, shrinking distances, and climate change. In the following text, we will look at some specific examples.
News Comparison of Biologics in the Treatment of Chronic Rhinosinusitis with Nasal Polyps
The authors of a meta-analysis of nine randomized controlled trials comparing dupilumab, omalizumab, and mepolizumab in patients with chronic rhinosinusitis and nasal polyps attempted to identify the most advantageous of the available biologics for this indication based on the ratio of benefits to risks.
News Myths Accompanying Therapy of Arterial Hypertension
Arterial hypertension is among the most common yet most underestimated diseases in the adult population. Misinterpretation of data and inadequate management of this disease can be caused, among other things, by an excessive amount of available clinical data and its incorrect analysis. Insufficient control of blood pressure (BP) is, however, one of the most significant factors in increased cardiovascular (CV) mortality.
News Efficacy and Safety of Etanercept in the Therapy of Arthritis
A review by experts from Genoa, Italy, focused on the available knowledge regarding the efficacy and safety of etanercept in the treatment of inflammatory rheumatic diseases.
News Is Dupilumab Effective in AD Therapy for Patients for Whom Cyclosporine A Fails or Cannot Be Given?
Severe forms of atopic dermatitis (AD) may require systemic therapy. However, the immunosuppressant cyclosporine A does not have sufficient efficacy in some patients with AD or is contraindicated for them. Therefore, the phase III clinical trial LIBERTY AD CAFÉ evaluated the efficacy of dupilumab in these patients.
News Fixed Combination of Trastuzumab and Pertuzumab for Subcutaneous Administration in Patients with Early Breast Cancer
At a symposium focused on breast cancer, held in December 2019 in San Antonio, Texas, preliminary results of the FeDeriCa clinical study were presented – comparing the pharmacokinetics, efficacy, and safety of a fixed combination of trastuzumab and pertuzumab for subcutaneous administration versus intravenous administration in patients with early-stage HER2-positive breast cancer. Based on the presented results, the drug received approval from the U.S. Food and Drug Administration (FDA).
News Long-term Safety and Efficacy of Ozanimod in the Treatment of Relapsing Forms of MS
Ozanimod is classified as a modulator of sphingosine-1-phosphate (S1P) receptors types 1 and 5. It is approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) and moderate to severe ulcerative colitis (UC) and continues to undergo intensive clinical research. The DAYBREAK open-label, single-arm study for participants with RRMS from previous trials with ozanimod was scheduled to be completed by January 2023, and its final results can therefore be expected soon. The following article presents the interim analysis results of this study 5 years after initiation.